CRBP Corbus Pharmaceuticals Holdings, Inc.
Price Chart
Executive Summary
Corbus reported Q1 2026 net loss of $23.0M ($1.23/share), slightly missing consensus EPS of -$1.22. The company highlighted FDA alignment on CRB-701 registrational path for HNSCC and cervical cancer, completed enrollment in the CANYON-1 obesity study with data expected summer 2026. Cash of $138.2M expected to fund operations into 2028.
Actionable Insight
Monotherapy CRB-701 data at ASCO 2026 (late May/early June) and CANYON-1 obesity data in summer 2026 are key catalysts. The slight EPS miss is negligible; focus on pipeline execution.
Key Facts
- Q1 2026 net loss $23.0M vs $17.0M a year ago
- EPS -$1.23 (consensus -$1.22, 2.5% miss)
- Cash and investments $138.2M at March 31, 2026
- FDA alignment achieved for CRB-701 registrational study in 2L HNSCC
- CANYON-1 Phase 1b obesity study fully enrolled (n=240), topline data expected summer 2026
Financial Impact
Net loss per share -$1.23 vs consensus -$1.22; operating expenses increased $4.5M YoY to $24.3M
Risk Factors
- Clinical trial failure risk for CRB-701 or CRB-913
- Dilution risk with $138M cash runway into 2028 but no revenue
- Competition in Nectin-4 ADC and obesity spaces
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3292746 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
May 26, 2026
19d ago
|
8-K
| $7.91 $7.75 | ▼ −2.02% | ▼ −3.11% | $8.19 (+3.54%) |
|
May 21, 2026
24d ago
|
8-K
| $11.51 $7.64 | ▼ −33.62% | ▼ −35.22% | $8.19 (−28.84%) |
|
May 14, 2026
4w ago
|
8-K
| $11.98 $11.51 | ▼ −3.92% | ▼ −3.21% | $8.19 (−31.64%) |
|
May 12, 2026
4w ago
|
8-K
| $11.43 $9.95 | ▼ −12.95% | ▼ −13.03% | $8.19 (−28.35%) |
|
May 12, 2026
4w ago
|
Press Release
| $11.43 $9.95 | ▼ −12.95% | ▼ −13.03% | $8.19 (−28.35%) |
|
Apr 16, 2026
8w ago
|
8-K
| $10.59 $10.06 | ▼ −5.00% | ▼ −5.56% | $8.19 (−22.66%) |
|
Apr 14, 2026
8w ago
|
8-K
| $10.02 $10.30 | ▲ +2.74% | ▲ +1.35% | $8.19 (−18.26%) |
|
Apr 7, 2026
9w ago
|
8-K
| $9.71 $10.02 | ▲ +3.19% | ▼ −2.14% | $8.19 (−15.65%) |
|
Mar 23, 2026
12w ago
|
EFFECT
| $8.43 $8.60 | ▲ +2.02% | ▲ +5.58% | $8.19 (−2.85%) |
|
Mar 11, 2026
13w ago
|
S-3
| $9.59 $8.94 | ▲ +6.78% | ▲ +5.80% | $8.19 (+14.60%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access